Corey Fishman and Steven Aronin, MD, discussed trial highlights of Orlynvah for uncomplicated urinary tract infections and outlining plans to seek partners for a market launch to address antibiotic resistance and enhance patient treatment options.
Steven Aronin, MD
Advertisement
SVP and Head of Clinical Development at Iterum Therapeutics.
Articles by Steven Aronin, MD
Iterum Therapeutics receives approval for Orlynvah as the first oral penem for treating uncomplicated urinary tract infections in adult women with limited treatment options.
Advertisement
Latest Updated Articles
SURE1 and REASSURE Trials Paved Way for FDA Approval of OrlynvahPublished: October 30th 2024 | Updated:
FDA Approves Oral Sulopenem (Orlynvah) for Uncomplicated Urinary Tract InfectionsPublished: October 29th 2024 | Updated: October 29th 2024
Advertisement
Advertisement
Trending on Contagion Live
1
Vaccines as a Secondary Strategy in the Fight Against Antimicrobial Resistance
2
Misdiagnosis Common in Skin Infections Due to Overlapping Noninfectious Conditions
3
Cefiderocol is Noninferior, But not "Game-Changer," for Gram-negative Bloodstream Infections
4
As NDM-CRE Infections Rise Significantly, Diagnostic Access Emerges as Weak Link
5
